Comparative Pharmacology
Head-to-head clinical analysis: CANTIL versus DARICON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CANTIL versus DARICON.
CANTIL vs DARICON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CANTIL (mepenzolate bromide) is a quaternary ammonium anticholinergic agent that blocks muscarinic acetylcholine receptors, reducing gastrointestinal motility and gastric acid secretion.
Daricon (oxyphencyclimine) is a competitive antagonist of muscarinic acetylcholine receptors (M1-M5), inhibiting parasympathetic nerve impulses. It reduces gastrointestinal motility, gastric acid secretion, and smooth muscle spasm by blocking cholinergic activity at effector cells.
50 mg orally three times daily, may increase to 100 mg three times daily if needed
5 mg orally three times daily. Maximum dose: 15 mg per day.
None Documented
None Documented
Terminal elimination half-life is approximately 10-12 hours; clinically, this supports twice-daily dosing in patients with normal renal function.
Terminal elimination half-life: 12-18 hours; clinical context: allows twice-daily dosing
Primarily renal excretion of unchanged drug and metabolites; approximately 60-70% eliminated renally, with about 30-40% excreted in feces via biliary elimination.
Renal (70% unchanged, 30% as metabolites); biliary/fecal (10%)
Category C
Category C
Anticholinergic / Antispasmodic
Anticholinergic